Apnimed
Michelle Guzman has a diverse work experience spanning multiple roles and companies. Michelle started their career at inSleep Health® as a Clinical Research and Education Manager in 2016. Michelle then joined The Johns Hopkins University School of Medicine, where they held positions as a Research Program Manager/RPSGT Clinical Research Coordinator and later as a Clinical Research Coordinator/Research Program Polysomnographic Technologist from 2010 to 2016. In 2016, Michelle began working as a Consultant at MG Consulting, specializing in clinical research, medical devices, and sleep medicine. At MG Consulting, they provided consultations to global CRO's and medical device companies regarding clinical research initiatives and FDA requirements. In 2019, Michelle worked as an IRB Regulatory Analyst at the University of Miami. Most recently, they joined Apnimed in 2020, first as a Clinical Operations Leader and then as a Senior Clinical Trial Manager starting in 2022.
Michelle Guzman holds a Bachelor's degree from Syracuse University. The field of study for their degree was not specified. Additionally, they have obtained a certification as a Registered Polysomnographic Technologist from the Board of Registered Polysomnographic Technologists. The specific month and year in which they obtained this certification were not provided.
This person is not in any offices
Apnimed
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed was founded in 2017 and is located in Cambridge, Massachusetts.